Skip to main content

Table 1 Anthropometric and clinical data of the study population

From: Metabolomic approach to profile functional and metabolic changes in heart failure

  Group A (N = 9) Group B (N = 9) Group C (N = 15)
Age (years) 64.9 ± 8.3 66.1 ± 7.9 66.7 ± 9.9
M/F 7/2 8/2 10/5
Height (m) 1.63 ± 0.06 1.67 ± 0.51 1.67 ± 0.45
Weight (kg) 67.2 ± 12.4 74.0 ± 10.6 72.9 ±9.6
BMI (kg/m2) 25.2 ± 3.2 26.4 ± 3.9 26.04 ± 2.7
BSA (m2) 1.74 ± 0.17 1.85 ± 0.20 1.84 ± 0.26
Diabetes 1 1 1
NYHA class
 I 9 8 0
 II 0 1 2
 III 0 0 13*
 IV 0 0 0
Aetiology
 Ischaemic 4 7
 Valvular 1 1
 DCM 4 6
 Hypertensive 0 1
 Other 0 0
Drugs
 β-blockers   9 14
 ACE-inhibitors 6 9
 ARBs 3 6
 Diuretics 7 15
 Aldosterone antagonists 3 5
 Ca-antagonists 4 1
 Antiarrythmics 1 2
 Acetylsalicylic acid 6 10
 Antiplatelet agents 0 1
 Anticoagulants 1 2
 Statins 7 9
 Other hypolipidemic agents 0 3
 Insulin 1 1
 Oral antidiabetic agents 1 1
 Digoxin 1 1
 Nitroderivates 2 0
 Other antihypertensive drugs 1 0
  1. BMI body mass index, BSA body surface area, DCM dilated cardiomyopathy
  2. * p < 0.02 vs Group B
\